Trastuzumab administered to patients with AJCC stage I (T1c) – III human epidermal growth factor receptor 2 (HER2) positive breast cancer who receive adjuvant chemotherapy
-
Percentage of female patients aged 18 and over with HER2/neu positive invasive breast cancer who are administered trastuzumab
CBE ID1858